Pharmaceutical Technology

OCTOBER 14, 2022

Merck Research Laboratories chief medical officer, global clinical development head and senior vice-president Dr Eliav Barr said: “This long-term collaboration combining Merck’s expertise in immuno-oncology with Moderna’s pioneering mRNA technology has yielded a novel tailored vaccine approach.

Vaccines 115

Vaccines Research Laboratories Immunity Immunization 115

Pharma Mirror

SEPTEMBER 9, 2021

Multiple flow chemistry platforms have been installed into a research laboratory at the site to allow the investigation of a wide range of chemical processes, including photolysis, electrochemistry and hydrogenations, as well. Announcement of the investment follows the appointment of Professor Ian R.

Research Laboratories 52

Research Laboratories 52

Pharmaceutical Business Review

DECEMBER 15, 2023

Merck Research Laboratories senior vice president for global clinical development and head of late-stage oncology Dr. Marjorie Green said: “In 2021, WELIREG became the first HIF-2α inhibitor therapy approved in the U.S. Furthermore, WELIREG showed an objective response rate (ORR) of 22% against 4% for everolimus.

Research Laboratories 64

Research Laboratories 64

European Pharmaceutical Review

APRIL 17, 2023

“I look forward to working with the Prometheus team to establish a new paradigm of precision treatment for immune diseases,” commented Dr Dean Y Li, President of Merck Research Laboratories.

Research Laboratories 93

Research Laboratories Immunity Immunization 93

Pharmaceutical Business Review

OCTOBER 16, 2023

Merck Research Laboratories global clinical development, late-stage oncology senior vice-president and head Dr Marjorie Green said: “This positive CHMP opinion builds on our efforts to treat advanced gastric and GEJ cancer in Europe, including in patients with HER2-negative disease, which accounts for vast majority of gastric cancer cases.

Chemotherapy 52

Chemotherapy Research Laboratories 52

Pharmaceutical Technology

JUNE 7, 2023

Merck Research Laboratories global clinical development vice-president Dr Elizabeth Rhee stated: “PREVYMIS has been an important addition to the care of high-risk adult CMV-seropositive patients who have received allogeneic stem cell transplants to help prevent CMV infection and disease.

Research Laboratories 52

Research Laboratories 52

Pharmacy Is Right For Me

APRIL 3, 2023

Pharmacists can work in a variety of settings, including hospitals, community pharmacies, research laboratories, and government agencies. Flexibility in work hours and settings Pharmacy offers a great deal of flexibility in terms of work hours and settings.

Research Laboratories 130

Research Laboratories Community Pharmacies Hospitals 130

Pharmaceutical Technology

JULY 13, 2022

Merck Research Laboratories president Dr Dean Li said: “Targeting CYP11A1 provides a compelling approach to suppressing the production of steroid hormones, a key driver of prostate cancer. “We The latest deal complements and bolsters the oncology pipeline of Merck.

Research Laboratories 105

Research Laboratories Vaccines 105

pharmaphorum

JUNE 30, 2022

. “The biopharmaceutical industry has only just started to harness the tremendous opportunity presented by emerging technological developments in AI and ML,” said Fiona Marshall, head of discovery, preclinical and translational medicine at Merck Research Laboratories.

Research Laboratories 119

Research Laboratories Drug Development Compounding 119

Express Pharma

FEBRUARY 8, 2024

Global biopharma companies and research laboratories recognize the value of investing in their workforce—training, upskilling, and certification—to unlock the full potential of employees and optimize available resources. The organization’s mission, “From insight to outcome,” underscores its commitment to delivering tangible results.

Research Laboratories 92

Research Laboratories Vaccines 92

European Pharmaceutical Review

OCTOBER 19, 2022

This is our second acquisition in gene therapy, following the 2021 acquisition of Prevail Therapeutics,” added Dr Daniel Skovronsky, Lilly’s Chief Scientific and Medical Officer and President of Lilly Research Laboratories. “With Akouos, we are optimistic that we can make a difference for people with hearing loss.”

Research Laboratories 93

Research Laboratories 93

Pharmaceutical Technology

APRIL 4, 2023

Results showed that patients treated with Padcev along with KEYTRUDA achieved a confirmed ORR of 68%. 12% experienced a complete response and 55% a partial response.

Research Laboratories 52

Research Laboratories Chemotherapy 52

European Pharmaceutical Review

NOVEMBER 22, 2022

Li, President of Merck Research Laboratories. “We Lysine-specific demethylase 1 (LSD1). Evidence indicates that LSD1 (KDM1A) plays an important role in the maturation of blood cells in the bone marrow,” noted Dr Dean Y.

Research Laboratories 94

Research Laboratories 94

Pharmaceutical Technology

FEBRUARY 27, 2023

Merck and Ridgeback intend to appeal the decision and request a re-examination of the regulator’s opinion. The scientific opinion of the EMA, which has supported 16 EU national authorities’ decision to make Lagevrio available, remains in effect.

Research Laboratories 64

Research Laboratories 64

European Pharmaceutical Review

DECEMBER 15, 2023

The companies also plan to expand the development programme to additional tumour types.

Vaccines 99

Vaccines Research Laboratories Immunity Immunization 99

Pharmaceutical Technology

MAY 12, 2023

They have also created tissue research images at the IPU and other ICR research laboratories. Researchers at the unit are integrating digital pathology, tissue hybridisation and AI technologies to gain better understanding of major aspects of cancer pathology.

Research Laboratories 52

Research Laboratories Hospitals 52

Pharmaceutical Technology

DECEMBER 23, 2022

Merck Research Laboratories president Dr Dean Li said: “Advances in ADC technologies are yielding a new generation of candidates designed to more precisely target and deliver potent anticancer agents to the tumour site. Merck will also make tiered royalty payments on net sales for any ADC product commercialised to Kelun-Biotech.

Research Laboratories 52

Research Laboratories 52

Express Pharma

APRIL 17, 2023

By applying a portfolio of powerful analytic tools to a comprehensive collection of IBD samples, Prometheus identified important disease insights that have now yielded a promising late-stage candidate,” said Dr Dean Y Li, President, Merck Research Laboratories.

Immunity 87

Immunity Immunization Research Laboratories Labelling 87

pharmaphorum

JANUARY 28, 2022

. “This approval demonstrates our progress in bringing Keytruda to patients with earlier stages of cancer, with the goal of helping more patients around the globe prevent disease recurrence,” said Scot Ebbinghaus, head of clinical research at Merck Research Laboratories.

Research Laboratories 110

Research Laboratories 110

Pharmaceutical Technology

JUNE 28, 2022

Merck Research Laboratories global clinical development head, senior vice-president and chief medical officer Dr Eliav Barr said: “Patients with germline BRCA-mutated, HER2-negative early breast cancer will often develop breast cancer at an earlier age than those without BRCA mutations, impacting people in their prime.

Research Laboratories 64

Research Laboratories Chemotherapy 64

European Pharmaceutical Review

AUGUST 18, 2022

We look forward to working with the talented scientific and technical teams at Orna.” ” “We are thrilled to collaborate with Merck, a company committed to breakthrough science, which has recognised the potential our platform can bring to patients.

Vaccines 90

Vaccines Research Laboratories Packaging 90

Pharmaceutical Technology

AUGUST 5, 2022

Merck Research Laboratories global clinical development head, senior vice-president and chief medical officer Dr Eliav Barr said: “The approval offers patients with germline BRCA-mutated, HER2-negative early-stage breast cancer a new, much-needed treatment option.

Research Laboratories 59

Research Laboratories Chemotherapy 59

European Pharmaceutical Review

JULY 7, 2022

At the beginning of his career in 2004, Dr Hughes was responsible for early clinical research at Bristol Myers-Squibb Company and then at Schering-Plough Research Institute. Dr Hughes earned his MD and PhD at Yale School of Medicine.

Research Laboratories 90

Research Laboratories Pharmaceutical Companies Pharmaceutical Companies Hospitals 90

Pharmaceutical Technology

JUNE 23, 2022

Merck Research Laboratories global clinical development senior vice-president, head and chief medical officer Dr Eliav Barr said: “Our goal with Vaxneuvance is to expand coverage of key invasive disease-causing serotypes and provide a strong immune response to serotypes that pose substantial risk to infants and children.

Vaccines 59

Vaccines Research Laboratories Immunity Immunization 59

LifeProNow

APRIL 30, 2023

We strongly believe in the results of the PROpel trial, which demonstrated the clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.”

Research Laboratories 130

Research Laboratories 130

Pharmaceutical Technology

AUGUST 17, 2022

The rights to the oRNA-LNP technology platform of Orna will be retained by the company, which will also progress various other fully owned programmes in oncology and genetic disease areas. In addition, Merck will make a $100m equity investment in Orna’s Series B funding round concluded recently.

Vaccines 59

Vaccines Research Laboratories Packaging 59

Express Pharma

AUGUST 29, 2023

The triad event is well-known to bring top international and home-grown machinery manufacturers, suppliers of analytical instruments and laboratory equipment, leading pharma companies, research laboratories, consultants, industry experts and key government officials under one roof to network and unlock business opportunities.

Research Laboratories 96

Research Laboratories Packaging 96

pharmaphorum

MAY 6, 2021

The company noted that Merck gained more than 100 regulatory approvals during Perlmutter’s seven-year tenure as president of Merck Research Laboratories, before retiring last year.

Research Laboratories 63

Research Laboratories 63

pharmaphorum

JULY 13, 2022

“Targeting CYP11A1 provides a compelling approach to suppressing the production of steroid hormones,” said Dean Li, president of Merck Research Laboratories. It is rumoured to be near to announcing a $40 billion takeover bid for the biotech.

Research Laboratories 52

Research Laboratories Compounding 52

Express Pharma

JULY 27, 2023

Global recruitment in V940-001 has begun, and the first patients are now enrolling in Australia.

Research Laboratories 89

Research Laboratories 89

pharmaphorum

APRIL 9, 2021

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories said in a statement that the data marked the first time an anti-PD-1 therapy showed potential adjuvant treatment for patients with RCC.

Research Laboratories 58

Research Laboratories 58

pharmaphorum

DECEMBER 23, 2022

. “Advances in ADC technologies are yielding a new generation of candidates designed to more precisely target and deliver potent anticancer agents to the tumour site,” said Dean Li, president of Merck Research Laboratories.

Research Laboratories 52

Research Laboratories 52

pharmaphorum

MARCH 2, 2021

Keytruda’s other indications remain unaffected, and Roy Baynes, head of global clinical development at Merck Research Laboratories emphasised that Keytruda remains “foundational” for treatment of certain patients with non-small cell lung cancer.

Research Laboratories 58

Research Laboratories Chemotherapy 58

pharmaphorum

AUGUST 5, 2020

Dr Sam Engel, associate vice president, Merck clinical research, diabetes and endocrinology, Merck Research Laboratories, said: “Data from phase 2 studies has provided compelling clinical evidence that warrants further evaluation of efinopegdutide for the treatment of NASH.”.

Diabetes 52

Diabetes Research Laboratories 52

pharmaphorum

SEPTEMBER 28, 2021

“Frequently diagnosed at an advanced stage, hepatocellular carcinoma has one of the highest mortality rates of solid cancers,” said Merck Research Laboratories’ clinical research head Scot Ebbinghaus. He said the company will “look forward to engaging with regulatory authorities as quickly as possible.”

Research Laboratories 52

Research Laboratories 52

pharmaphorum

SEPTEMBER 9, 2020

Discontinuations due to AEs were more frequent in the 45 mg group (15% in COUGH-1 and 20% in COUGH-2) compared to the 15 mg (3% in COUGH-1 and 8% in COUGH-2) and placebo groups (3% and 5%, respectively).

Research Laboratories 52

Research Laboratories Dosage 52

pharmaphorum

OCTOBER 14, 2021

Dr Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said the data showing a 36% reduction in the risk of death “are compelling”.

Chemotherapy 45

Chemotherapy Research Laboratories Immunity Immunization 45